Amy Bennett

Quality improvement in neurology: Epilepsy Update Quality Measurement Set.

Epilepsy is a common, debilitating, and costly disease. It is estimated that 2.2 million people in the United States are diagnosed with epilepsy, and 150,000 new cases of epilepsy are diagnosed in the United States annually.1 However, epilepsy prevalence might be underestimated due to numerous social issues that accompany a diagnosis of epilepsy.2 People with epilepsy have poorer overall health status, impaired intellectual and physical functioning, and a greater risk for accidents and injuries.1–3 It is estimated that the annual direct medical cost of epilepsy in the United States is

Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.

9.6 billion, and this estimate does not include indirect costs from losses in quality of life or productivity.1

Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary

All clinicians believe they provide quality care, yet most clinicians do not directly measure quality parameters in their practice to provide verifiable health care outcomes.1 Quality measures related to a chronic disease provide reportable and repeatable measures that can either document performance of quality care or identify gaps in care for future action/improvement. Disease-specific quality measures in neurology provide a framework that can assist clinicians in practice measurement and modification; these have the potential to benefit both subspecialist and generalist alike. Multiple sclerosis (MS) is a common, chronic, and ultimately disabling disease with multiple potential clinical intervention points during its course. It is therefore appropriate to have quality measures specific for this condition that span the course of the disease.

Quality improvement in neurology Dementia management quality measurement set update

Approximately 630,000 people in the United States carried a diagnosis of Parkinson disease (PD) in 2010, and worldwide estimates indicate that up to 10 million individuals may be diagnosed currently.1,2 The national economic burden of PD was estimated to exceed

Quality improvement in neurology: Neuro-oncology quality measurement set

14.4 billion in 2010.1 PD is a heterogeneous disorder with motor and nonmotor features that are often underdiagnosed and, in turn, provided limited treatment options. The American Academy of Neurology (AAN) created a quality measurement set in 2010 to provide a framework for measuring progress on addressing these treatment gaps in care.3

Quality improvement in neurology: Stroke and Stroke Rehabilitation Quality Measurement Set update

Dementia is a neurologic condition manifested by a substantial decline in multiple cognitive abilities that collectively render a person unable to function at expected levels and progressively impede independent ability to perform everyday activities. For decades, public health officials have warned of the coming tsunami of Alzheimer disease (AD), and dementia has even been characterized as the dominant scourge of modern times, replacing cancer.1 Recently, hopeful signs have appeared, including reports from some longitudinal research studies that incidence of dementia is declining,2 and from the federal government that research funding for AD and other dementias will approach

Quality Improvement in Neurology: Neurotology Quality Measurement Set:

1 billion USD in 2017.3

Quality improvement in neurology: Neuro-Oncology Quality Measurement Set

Over 78,000 new CNS tumors are diagnosed each year in the United States, nearly one-third of which are primary malignant brain tumors,1 and the US prevalence of primary brain tumors is approximately 688,000.2 While primary CNS neoplasms represent only 1.4% of new cancer diagnoses, approximately 2.7% of cancer deaths are related to CNS neoplasms,3 and it is estimated that 16,947 deaths will result from primary CNS tumors in 2017.1 Population-based studies have shown that socioeconomic disparities are present within the neuro-oncology community,4–7 highlighting the need for a unified system of quality metrics in this growing field. Toward this end, several authors have published work on quality-based practice and on the inclusion of patient-reported outcomes in brain tumor care.8–12

Quality Improvement in Neurology: Essential Tremor Quality Measurement Set

Stroke is the fifth leading cause of death in the United States and the second leading cause of disability worldwide.1,2 “On average, every 40 seconds, someone in the United States has a stroke, and someone dies of one approximately every 4 minutes.”3 Each year, nearly 800,000 people experience stroke, with up to 185,000 experiencing recurrent stroke events.3 Strokes occur at any age, and risk increases with age.4 Nearly half of older stroke survivors experience moderate to severe disability.5

Quality Improvement in Neurology: Dementia Management Quality Measurement Set Update

Quality Improvement in Neurology: Neurotology Quality Measurement Set Otolaryngology– Head and Neck Surgery 2018, Vol. 159(4) 603–607 American Academy of Otolaryngology–Head and Neck Surgery Foundation and American Academy of Neurology Institute 2018 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/0194599818790947 http://otojournal.org Habib Rizk, MD, MSc, Yuri Agrawal, MD, MPH, Susan Barthel, Marc L. Bennett, MD, MMHC, Joni K. Doherty, MD, PhD, Patricia Gerend, Daniel R. Gold, DO, David Morrill, John G. Oas, MD, J. Kirk Roberts, MD, Erika Woodson, MD, David A. Zapala, PhD, Amy Bennett, JD, and Anant M. Shenoy, MD